Traws Pharma, Inc.(TRAW)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Traws Pharma, Inc. (TRAW) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TRAW at 29.7/100 on a 32-signal composite quality model, placing it at rank #2,520 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of TRAW by reported 13-F value include ORBIMED ADVISORS, Ally Bridge Group (NY), ADAGE CAPITAL PARTNERS GP, L.L.C., based on the most recent SEC filings. TRAW trades on the Nasdaq exchange and files with the SEC under CIK 1130598. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TRAW daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Traws Pharma, Inc. directly from SEC EDGAR.
AI Quality Score
29.7/100
AI Rank
#2,520
Net Income
$-3.1M
TRAW key financials by period
Traws Pharma, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$2.8M
$9.2M
—
FY 2024
10-K
$226.0K
$-166.5M
—
FY 2023
10-K
$226.0K
$-18.9M
—
FY 2022
10-K
$226.0K
$-19.0M
—
FY 2021
10-K
$226.0K
$-16.2M
—
FY 2020
10-K
$231.0K
$-25.2M
—
Institutions holding TRAW
Institutional investors reporting a position in Traws Pharma, Inc. on SEC Form 13F.
